Kane Biotech Beheer

Beheer criteriumcontroles 2/4

De CEO Kane Biotech is Marc Edwards, benoemd in Sep2018, heeft een ambtstermijn van 6.17 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 406.83K, bestaande uit 61.5% salaris en 38.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.64% van de aandelen van het bedrijf, ter waarde CA$ 702.14K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 6.2 jaar.

Belangrijke informatie

Marc Edwards

Algemeen directeur

CA$406.8k

Totale compensatie

Percentage CEO-salaris	61.5%
Dienstverband CEO	6.2yrs
Eigendom CEO	4.6%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Marc Edwards's beloning veranderd ten opzichte van Kane Biotech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$5m
Mar 31 2024	n/a	n/a	-CA$5m
Dec 31 2023	CA$407k	CA$250k	-CA$5m
Sep 30 2023	n/a	n/a	-CA$4m
Jun 30 2023	n/a	n/a	-CA$4m
Mar 31 2023	n/a	n/a	-CA$4m
Dec 31 2022	CA$303k	CA$242k	-CA$4m
Sep 30 2022	n/a	n/a	-CA$4m
Jun 30 2022	n/a	n/a	-CA$5m
Mar 31 2022	n/a	n/a	-CA$5m
Dec 31 2021	CA$329k	CA$225k	-CA$5m
Sep 30 2021	n/a	n/a	-CA$4m
Jun 30 2021	n/a	n/a	-CA$4m
Mar 31 2021	n/a	n/a	-CA$3m
Dec 31 2020	CA$353k	CA$225k	-CA$4m
Sep 30 2020	n/a	n/a	-CA$4m
Jun 30 2020	n/a	n/a	-CA$4m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	CA$311k	CA$225k	-CA$960k
Sep 30 2019	n/a	n/a	-CA$510k
Jun 30 2019	n/a	n/a	-CA$685k
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	CA$85k	CA$67k	-CA$3m
Sep 30 2018	n/a	n/a	-CA$4m
Jun 30 2018	n/a	n/a	-CA$4m
Mar 31 2018	n/a	n/a	-CA$4m
Dec 31 2017	CA$18k	n/a	-CA$3m

Compensatie versus markt: De totale vergoeding ($USD 291.06K ) Marc } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 169.13K ).

Compensatie versus inkomsten: De vergoeding van Marc is gestegen terwijl het bedrijf verliesgevend is.

CEO

Marc Edwards

6.2yrs

Tenure

CA$406,832

Compensatie

Mr. Marc Edwards is the Founder and President of VetRx, a Montreal-based technology company specializing in daollection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. Mr....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Marc Edwards	President	6.2yrs	CA$406.83k	4.64% CA$ 702.1k
Ray Dupuis	Chief Financial Officer	7.2yrs	CA$231.39k	0.72% CA$ 108.4k
Robert Huizinga	Executive Chairman & Member of Scientific Advisory Board	6.2yrs	geen gegevens	0.24% CA$ 36.5k
Gregory Schultz	Chief Scientific Officer & Member of Scientific Advisory Board	2.6yrs	geen gegevens	geen gegevens
Lorne Gorber	Investor Relations	no data	geen gegevens	geen gegevens
Wendy Nachtigall	Director of Marketing	no data	geen gegevens	geen gegevens
Lori Christofalos	Chief Quality Officer	less than a year	geen gegevens	geen gegevens
Nicole Sendey	Investor Relations Adviser	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van KNE wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marc Edwards	President	8.8yrs	CA$406.83k	4.64% CA$ 702.1k
Robert Huizinga	Executive Chairman & Member of Scientific Advisory Board	6.2yrs	geen gegevens	0.24% CA$ 36.5k
Gregory Schultz	Chief Scientific Officer & Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Georges Morin	Independent Director	4.5yrs	CA$41.53k	0.11% CA$ 16.5k
Philip Renaud	Vice Chairman	14.2yrs	CA$44.73k	18.46% CA$ 2.8m
Rashieda Gluck	Member of Scientific Advisory Board	6.2yrs	CA$13.30k	geen gegevens
Gordon Guay	Chairman of Scientific Advisory Board	6.2yrs	geen gegevens	geen gegevens
John Coleman	Independent Director	less than a year	CA$2.25k	geen gegevens

6.2yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van KNE wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Kane Biotech Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Kane Biotech Inc., Annual General Meeting, May 22, 2024

Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair

Kane Biotech Inc. Appoints John Coleman to the Board of Directors

Less than half of directors are independent

Kane Biotech Inc. Appoints Dr. Gregory Schultz as Chief Scientific Officer

Vice Chairman exercised options to buy CA$200k worth of stock.

Recent updates

Kane Biotech Inc. to Report Q3, 2024 Results on Nov 28, 2024

Kane Biotech Inc. Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel

Kane Biotech Inc. (TSXV:KNE) signed a letter of intent to acquire FB Dermatology S.r.l.

New major risk - Market cap size

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.007 loss in 2Q 2023)

Kane Biotech Inc. to Report Q2, 2024 Results on Aug 29, 2024

Kane Biotech Inc. Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel

Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global

First quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 1Q 2023)

Kane Biotech Inc. to Report Q1, 2024 Results on May 23, 2024

Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc. (TSXV:KNE).

Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc. (TSXV:KNE).

Full year 2023 earnings released: CA$0.04 loss per share (vs CA$0.032 loss in FY 2022)

Kane Biotech Inc. to Report Q4, 2023 Results on Mar 26, 2024

Kane Biotech Inc., Annual General Meeting, May 22, 2024

Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair

Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray

An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc. (TSXV:KNE).

Third quarter 2023 earnings released: CA$0.011 loss per share (vs CA$0.008 loss in 3Q 2022)

Kane Biotech Inc. to Report Q3, 2024 Results on Nov 28, 2023

Kane Biotech Inc. Appoints John Coleman to the Board of Directors

New major risk - Share price stability

Kane Biotech Inc. and ProgenaCare Global Launch Newly Rebranded Revyve Antimicrobial Wound Care Fall Forum

Kane Biotech Inc. to Exhibit At Symposium on Advanced Wound Care Fall Forum

New minor risk - Shareholder dilution

Kane Biotech Inc. announced that it has received CAD 0.5 million in funding

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in 2Q 2022)

Kane Biotech Inc. to Report Q2, 2023 Results on Aug 29, 2023

Kane Biotech Inc. announced that it expects to receive CAD 0.5 million in funding

First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 1Q 2022)

Kane Biotech Inc. Announces FDA 510(k) Clearance for its Coactiv+™? Antimicrobial Wound Gel

Kane Biotech Inc. to Report Q1, 2023 Results on May 25, 2023

Full year 2022 earnings released: CA$0.03 loss per share (vs CA$0.041 loss in FY 2021)

Less than half of directors are independent

Kane Biotech Inc. Announces First Distribution Agreement for coactiv+™ Antimicrobial Hydrogel

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.013 loss in 3Q 2021)

Kane Biotech Inc. to Report Q3, 2022 Results on Nov 24, 2022

Kane Biotech Inc. Announces 510(K) Submission for Its Coactiv+™ Antimicrobial Hydrogel

Second quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.008 loss in 2Q 2021)

Kane Biotech Inc. to Report Q2, 2022 Results on Aug 25, 2022

First quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.008 loss in 1Q 2021)

Kane Biotech Inc. to Report Q1, 2022 Results on May 26, 2022

Kane Biotech Inc. announced that it has received CAD 1 million in funding

Kane Biotech Inc. Appoints Dr. Gregory Schultz as Chief Scientific Officer

Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.009 loss in 3Q 2020)

Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.005 loss in 2Q 2020)

Kane Biotech Inc. Expands its Wound Care and Surgical Portfolio with a coactiv+TM Antimicrobial Hydrogel

Kane Biotech Inc. Prepares its First Batch of DispersinB®

Is Kane Biotech (CVE:KNE) A Risky Investment?

First quarter 2021 earnings released

Vice Chairman exercised options to buy CA$200k worth of stock.

Is Kane Biotech (CVE:KNE) A Risky Investment?

Full year 2020 earnings released

Kane Biotech Inc. to Report Q4, 2020 Results on Mar 25, 2021

Kane Biotech Inc. Announces Executive Changes

Kane Biotech Inc. Announces Launch of New Human Health OTC DermaKB™ Product Line

Kane Biotech Inc. to Report Q3, 2020 Results on Nov 26, 2020

Kane Biotech Builds Upon Successful Results with Launch of A US Consumer Test

Kane Biotech Inc. Enters into an Agreement with Animalcare Group PLC to Form STEM Animal Health Inc

First half earnings released

Kane Biotech Inc. to Report Q2, 2020 Results on Aug 27, 2020

Kane Biotech Inc.(TSXV:KNE) dropped from S&P/TSX Venture Composite Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam